Wczytywanie spółki
Just reported
Q3 2026 results
From Progyny's results release of 4 listopada 2026; its quarterly report has since been filed.
Revenue
Actual
341,3M USD
+8,9% y/y
-2,6% q/qGuided
340M USD
midpoint
Within guide+0,4%EPS, GAAP
Actual
0,32 USD
+113% y/y
-5,9% q/qGuided
—
No guide given
Operating income, GAAP
Actual
35,2M USD
+63% y/y
-12% q/qGuided
—
No guide given
Company outlook
Q4 2026
- Revenue344,7M USD – 364,7M USD+11% y/y First given
- EPS, adjusted0,53 USD – 0,58 USDFirst given
Full year 2026
- Revenue1,365B USD – 1,385B USD+6,7% y/y Unchanged
- EPS, adjusted2,09 USD – 2,13 USDRaised +1,9%
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Progyny is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Healthcare Plans
Graded A or B and worth $2B or more: A first, then the largest.
CVSCVS Health Corp114,9B USDA
CIThe Cigna Group78,1B USDA
OSCROscar Health, Inc.9,9B USDA
CLOVClover Health Investments, Corp.2,6B USDA
HUMHumana Inc.53,3B USDB
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 paź 2026CBGraded C, now B
MCKMckesson Corporation4 lis 2026BAGraded B, now A- CVSCVS Health Corp4 lis 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 lis 2026BAGraded B, now A
BIIBBiogen Inc.28 paź 2026BAGraded B, now A
Pełne sprawozdania finansowe →
Zbudowane z własnych raportów spółki Progyny, Inc. składanych do amerykańskiej Komisji Papierów Wartościowych i Giełd (SEC). Liczby są takie, jak zaraportowano, a historia na akcję przeliczona na dzisiejszą bazę akcji. To opisuje firmę — nie jest poradą inwestycyjną ani rekomendacją kupna lub sprzedaży.
